diagnomics

Diagnomics Celebrates the Announcement of the Successful Initial Public Offering (IPO) and Listing of Eone-Diagnomics Genome Center (EDGC) on the Korea Securities Dealer Automated Quotation (KOSDAQ)

July 3, 2018Diagnomics

SAN DIEGO, July 2, 2018 – Diagnomics, Inc., a leading provider for precision medicine solutions based on genomics technology, proudly shares the announcement of the successful initial public offering (IPO) and listing of Eone-Diagnomics Genome Center (ticker symbol; EDGC) on the Korea Securities Dealer Automated Quotation (KOSDAQ) on June 26, 2018.

Eone-Diagnomics Genome Center (EDGC) is an international joint venture established in 2013 between the largest clinical laboratory in South Korea, Eone Life Science, in Incheon, South Korea and Diagnomics Inc. in California, USA. EDGC offers cutting-edge products and services in clinical and consumer genetics, ushering forth innovation in healthcare based on big-data and genome analysis utilizing next generation sequencing (NGS) and array technologies.

EDGC has been recognized as one of the most popular listings in KOSDAQ market as an international joint venture in biotechnology. Many foreign companies view EDGC’s IPO as a prominent success story, spotlighting Korea to be an ideal country for international business cooperation in emerging biotechnology and healthcare fields. The company said the IPO would promote further global cooperation and market expansion through leading-edge technologies and product development.

“This is exciting news for EDGC, their employees, their customers, and investors,” said Dr. Byung-In Lee, CEO of Diagnomics. “This extraordinarily talented and capable team of professionals worked hard to make this happen and we are proud to be a part of this successful joint venture with Eone Laboratories, demonstrating a big step toward the international reach and impact of the Diagnomics team in San Diego.” Dr. Min Seob Lee, co-CEO of EDGC and a founder of Diagnomics and EDGC stated, “This was a highly competitive IPO and a historical landmark as an international joint venture in the biotechnology industry. We are looking forward to collaborating our respective strengths and furthering our reach as a leader in the global genomics market, advancing the impact of genomics in health.”

About Diagnomics

Diagnomics, Inc. is a trusted provider of innovative genetic testing platforms for both organizations and individual consumers. We strive to deliver confidence and reliability by offering comprehensive genomic solutions for the development of personalized healthcare and precision medicine in the global genomics market.

Diagnomics is a CLIA-certified, CAP-accredited, and HIPAA-compliant laboratory providing genetic testing platform services and cloud-based analysis solutions. To learn more, visit www.diagnomics.com

Contact: Byung-In Lee

Telephone: (760) 310-5984

Main Number: (800) 605-8422

Email: info@diagnomics.com

Website: www.diagnomics.com

[Diagnomics’ 2018 Fall Campaign] All CLIA-Grade GSA & WES Promotion

Diagnomics Celebrates the Announcement of the Successful Initial Public Offering (IPO) and Listing of Eone-Diagnomics Genome Center (EDGC) on the Korea Securities Dealer Automated Quotation (KOSDAQ)